Miranda Jayne Toledano - 07 Aug 2026 Form 4 Insider Report for Entera Bio Ltd. (ENTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ENTX
Reported as of: 07 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 16:19:06 UTC
Prior SEC filing: 16 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact

Key filing fact

Miranda Jayne Toledano filed Form 4 for Entera Bio Ltd. (ENTX) on 07 Aug 2026.

Key facts

This page summarizes Miranda Jayne Toledano's Form 4 filing for Entera Bio Ltd. (ENTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 07 Aug 2026, 16:19.

Change

Previous filing in this sequence was filed on 16 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686530 Primary reporting owner

Toledano Miranda Jayne

Relationship: Chief Executive Officer, Director
Address: KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM, ISRAEL
Signature: /s/ Dana Yaacov-Garbeli, Attorney-in-Fact
Signature date: 07 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ENTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +500,000
Change %
Price: $0.000000^*
Shares after: 500,000
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 500,000
Exercise price: $1.37
Footnotes: F1

ENTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +200,000
Change %
Price: $0.000000^*
Shares after: 200,000
Date: 07 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares, par value NIS 0.0000769 per share
Underlying amount: 200,000
Exercise price: $2.81
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

Footnote F2

Represents a grant of options to purchase ordinary shares. This grant of options was originally approved by the Board on July 15, 2022, subject to (i) approval by the Company's shareholders, which was obtained on September 7, 2022, (ii) the occurrence of a Triggering Event (as defined and specified in Ms. Toledano's employment agreement), which was satisfied upon the Company obtaining the necessary resources to fund its Phase 3 trial through the consummation of the Company's July 2026 financing transaction, and (iii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a four-year period that commenced on August 7, 2026, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.